Eli Lilly partners with SCRI and with Dana-Farber on cancer research

17 June 2015

US pharma major Eli Lilly (NYSE: LLY) has entered into a strategic partnership with the Sarah Cannon Research Institute (SCRI) to co-develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor.

Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway.

"Lilly has a long history of leading innovation in cancer therapy with the goal to offer patients improved treatment outcomes," said Christopher Slapak, vice president, early phase clinical research for Lilly. "This strategic partnership is an exciting step to foster further collaboration with SCRI in advancing the field of cancer research," Dr Slapak added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK